sarepta therapeutics fda - Search News

Order byBest matchMost fresh

News

Sarepta stock extends decline

Sarepta Therapeutics stock sinks after FDA tells company to stop shipping its bestselling drug

Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an unrelated drug.

Continue reading

· 15h · on MSN

Sarepta stock extends decline as company declines FDA call to withdraw drug

· 14h · on MSN

Sarepta extends losses premarket after refusing FDA’s halt request

FDA Shuts Down Sarepta Gene Therapy Trials

Fierce Pharma · 9h

Sarepta stands behind Elevidys after FDA requests gene therapy be pulled from market

As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head, the biotech is standing firm behind its approved Duchenne muscular dystrophy (DMD) treatment. | As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head,

Continue reading

BioPharma Dive · 4h

FDA asks Sarepta to stop shipping Duchenne gene therapy

· 4h · on MSN

Sarepta Therapeutics laying off dozens in Ohio, won't comply with FDA request to halt therapy

Devdiscourse43m

Sarepta Therapeutics Temporarily Halts Elevidys Shipments in Compliance with FDA Requests

Sarepta Therapeutics Inc has voluntarily paused shipments of Elevidys in the United States. The decision responds to FDA ...

11h

Sarepta Therapeutics: Why Is SRPT Stock Crashing?

The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

4h

Sarepta under pressure: FDA requests halt of Elevidys shipments

Sarepta Therapeutics (SRPT) stock is in focus after the US Food and Drug Administration (FDA) asked the company to halt ...

12h

Sarepta's Shocking Stand: Company Rejects FDA Request To Pull Gene Therapy Elevidys

FDA places clinical hold on Sarepta's LGMD gene therapy trials after three deaths and revokes platform tech designation due ...

Sarepta Therapeutics crisis is huge blow to Duchenne families, company

The FDA will request Sarepta Therapeutics stop all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results